Cell-Type Specific Gene Expression Signature in Liver Underlies Response to Interferon Therapy in Chronic Hepatitis C Infection

Gastroenterology

Volumn 138, Issue 3, 2010, Pages

  Chen, Limin ^a,b   Borozan, Ivan ^a   Sun, Jing ^a   Guindi, Maha ^b   Fischer, Sandra ^b   Feld, Jordan ^b   Anand, Nitasha ^b   Heathcote, Jenny ^b   Edwards, Aled M ^a,b   McGilvray, Ian D ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gene Expression Profiling; HCV Response Signature; Multivariate Analysis; Prospective Validation

Indexed keywords

DNA; INTERFERON; INTERFERON STIMULATED GENE FACTOR 15; INTERFERON STIMULATED GENE FACTOR 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ACTIVATION; CELL TYPE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FIBROSIS; GENE EXPRESSION; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KUPFFER CELL; LIVER BIOPSY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; UPREGULATION; VIRUS LOAD;

EID: 77249169773     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.10.046     Document Type: Article

References (42)

1. National Institutes of Health Consensus Development Conference statement. management of hepatitis. Hepatology 36 Suppl 1 (2002) S3-S20
2. Poynard T., Yuen M.F., Ratziu V., et al. Viral hepatitis C. Lancet 362 (2003) 2095-2100
3. Willems M., Metselaar H.J., Tilanus H.W., et al. Liver transplantation and hepatitis C. Transpl Int 15 (2002) 61-72
4. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 36 (2002) S237-S244
5. Selzner N., Chen L., Borozan I., et al. Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients. J Hepatol 48 (2008) 708-713
6. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
7. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
8. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al., PEGASYS International Study Group. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
9. Wright T.L. Treatment of patients with hepatitis C and cirrhosis. Hepatology 36 5 Suppl 1 (2002) S185-S194
10. Reddy K.R., Hoofnagle J.H., Tong M.J., et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30 (1999) 787-793
11. Kinzie J.L., Naylor P.H., Nathani M.G., et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 8 (2001) 264-269
12. De Maria N., Colantoni A., Idilman R., et al. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology 49 (2002) 788-792
13. Missiha S., Heathcote J., Arenovich T., et al., Canadian Pegasys Expanded Access Group. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 102 (2007) 2181-2188
14. Huang Y., Yang H., Borg B.B., et al. A functional SNP of interferon-γ gene is important for interferon-α-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A 104 (2007) 985-990
15. Yee L.J., Tang J., Gibson A.W., et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33 (2001) 708-712
16. Chen L., Borozan I., Feld J., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 (2005) 1437-1444
17. Lempicki R.A., Polis M.A., Yang J., et al. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 193 (2006) 1172-1177
18. Asselah T., Bieche I., Narguet S., et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57 (2008) 516-524
19. Asahina Y., Izumi N., Komatsu N., et al. Gene expression involving interferon-regulatory innate immunity and resistance to PEG-interferon alfa-2b plus ribavirin treatment in chronic hepatitis C. Hepatology 4 Suppl 1 (2006) A220
20. Borozan I., Chen L., Sun J., et al. Gene expression profiling of acute liver stress during living donor liver transplantation. Am J Transplant 6 (2006) 806-824
21. Chen L., Borozan I., Milkiewicz P., et al. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid. Liver Int 28 (2008) 997-1010
22. Borozan I., Chen L., Paeper B., et al. MAID: an effect size based model for microarray data integration across laboratories and platforms. BMC Bioinformatics 9 (2008) 305
23. Gentleman R.C., Carey V.J., Bates D.M., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5 (2004) R80
24. Borgogna C., Toniutto P., Smirne C., et al. Expression of the interferon-inducible proteins MxA and IFI16 in liver allografts. Histopathology 54 (2009) 837-846
25. Macquillan G.C., de Boer W.B., Allan J.E., et al. Hepatocellular MxA protein expression supports the differentiation of recurrent hepatitis C disease from acute cellular rejection after liver transplantation. Clin Transplant (2009) [Epub ahead of print]
26. MacQuillan G.C., de Boer W.B., Platten M.A., et al. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection. J Med Virol 68 (2002) 197-205
27. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
28. Dudoit S., and Fridlyand J. A prediction-based resampling method for estimating the number of clusters in a dataset. Genome Biol 3 (2002) RESEARCH0036
29. Randall G., Chen L., Panis M., et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131 (2006) 1584-1591
30. Brunt E.M. Pathology of hepatic iron overload. Semin Liver Dis 25 (2005) 392-401
31. Brooks D.G., Trifilo M.J., Edelmann K.H., et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12 (2006) 1301-1309
32. Selzner N., and McGilvray I. Can genetic variations predict HCV treatment outcomes?. J Hepatol 49 (2008) 494-497
33. Ge D., Fellay J., Thompson J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (2009) 399-401
34. Lusida M.I., Nagano-Fujii M., Nidom C.A., et al. Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a. J Clin Microbiol 39 (2001) 3858-3864
35. Kim K.A., Lin W., Tai A.W., et al. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol 50 (2009) 705-711
36. Asahina Y., Izumi N., Hirayama I., et al. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology 134 (2008) 1396-1405
37. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
38. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105 (2008) 7034-7039
39. Mossman K.L., Macgregor P.F., Rozmus J.J., et al. Herpes simplex virus triggers and then disarms a host antiviral response. J Virol 75 (2001) 750-758
40. Villacres M.C., Literat O., DeGiacomo M., et al. Defective response to Toll-like receptor 3 and 4 ligands by activated monocytes in chronic hepatitis C virus infection. J Viral Hepat 15 (2008) 137-144
41. Woitas R.P., Petersen U., Moshage D., et al. HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. World J Gastroenterol 8 (2002) 562-566
42. Waggoner S.N., Hall C.H., Hahn Y.S., et al. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol 82 (2007) 1407-1419